Effectiveness and persistence of golimumab as a second biological drug in patients with spondyloarthritis A retrospective study

This observational, longitudinal retrospective, noncomparative study was designed to assess the persistence and effectiveness of golimumab as a second anti-tumor necrosis factor (TNF) drug in patients with spondyloarthritis requiring discontinuation from a first anti-TNF drug. Data were collected re...

Descripción completa

Detalles Bibliográficos
Autores: Alegre-Sancho, JJ, Juanola, X, Rodriguez-Heredia, JM, Manero, J, Villa-Blanco, I, Laiz, A, Arteaga, MJ, Cea-Calvo, L, Gonzalez, CM
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p4799
Acceso en línea:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4799
https://ddd.uab.cat/record/272006
Access Level:acceso abierto
Palabra clave:ankylosing spondylitis
anti- tumor necrosis factor
golimumab
psoriatic arthritis
spondyloarthritis
tumor necrosis factor inhibitor
id ES_cd69dfd1b722f7d6ddb72c4d06c3d921
oai_identifier_str oai:iibsantpau.fundanetsuite.com:p4799
network_acronym_str ES
network_name_str España
repository_id_str
spelling Effectiveness and persistence of golimumab as a second biological drug in patients with spondyloarthritis A retrospective studyAlegre-Sancho, JJJuanola, XRodriguez-Heredia, JMManero, JVilla-Blanco, ILaiz, AArteaga, MJCea-Calvo, LGonzalez, CMankylosing spondylitisanti- tumor necrosis factorgolimumabpsoriatic arthritisspondyloarthritistumor necrosis factor inhibitorThis observational, longitudinal retrospective, noncomparative study was designed to assess the persistence and effectiveness of golimumab as a second anti-tumor necrosis factor (TNF) drug in patients with spondyloarthritis requiring discontinuation from a first anti-TNF drug. Data were collected retrospectively for all patients with axial spondyloarthritis or psoriatic arthritis from 20 rheumatology clinics in Spain who started golimumab as a second anti-TNF drug between January 2013 and December 2015. Golimumab persistence was assessed with Kaplan-Meier survival analysis, and associated factors were assessed with Cox regression analysis. 210 patients started golimumab as a second anti-TNF drug: 131 with axial spondyloarthritis and 79 with psoriatic arthritis. In axial spondyloarthritis patients, the mean (standard deviation) Bath Ankylosing Spondylitis Disease Activity Index score at baseline was 5.5 (2.1), decreasing to 3.9 (2.0) at month 3 and 3.5 (2.0) at year 1, and remaining stable thereafter. In psoriatic arthritis patients, mean (standard deviation) baseline Disease Activity Score was 4.0 (1.3), reducing to 2.5 (1.2) at month 3 and to 2.2 (1.3) at year 1. Corresponding improvements were recorded from baseline in C-reactive protein levels and erythrocyte sedimentation rates. The probability of persistence of treatment with golimumab was 80% at year 1, 70% at year 2 and 65% at years 3 and year 4, and was similar in those who had stopped the first anti-TNF due to loss of efficacy or other reasons. Cox regression analysis showed that the probability of survival with golimumab was higher in patients with higher erythrocyte sedimentation rate, in patients with axial spondyloarthritis than with psoriatic arthritis, and in those who had discontinued adalimumab as first anti-TNF. Seventy-two patients (34.3%) discontinued golimumab during follow-up, 50 of them due to lack of efficacy. In patients with spondyloarthritis requiring discontinuation from a first anti-TNF drug, treatment with golimumab was effective and showed a high probability of persistence up to 4 years of treatment.LIPPINCOTT WILLIAMS & WILKINS2021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4799https://ddd.uab.cat/record/272006MEDICINEISSN: 00257974ISSNe: 15365964reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pauinstname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)Inglésinfo:eu-repo/semantics/openAccessoai:iibsantpau.fundanetsuite.com:p47992026-06-14T12:41:47Z
dc.title.none.fl_str_mv Effectiveness and persistence of golimumab as a second biological drug in patients with spondyloarthritis A retrospective study
title Effectiveness and persistence of golimumab as a second biological drug in patients with spondyloarthritis A retrospective study
spellingShingle Effectiveness and persistence of golimumab as a second biological drug in patients with spondyloarthritis A retrospective study
Alegre-Sancho, JJ
ankylosing spondylitis
anti- tumor necrosis factor
golimumab
psoriatic arthritis
spondyloarthritis
tumor necrosis factor inhibitor
title_short Effectiveness and persistence of golimumab as a second biological drug in patients with spondyloarthritis A retrospective study
title_full Effectiveness and persistence of golimumab as a second biological drug in patients with spondyloarthritis A retrospective study
title_fullStr Effectiveness and persistence of golimumab as a second biological drug in patients with spondyloarthritis A retrospective study
title_full_unstemmed Effectiveness and persistence of golimumab as a second biological drug in patients with spondyloarthritis A retrospective study
title_sort Effectiveness and persistence of golimumab as a second biological drug in patients with spondyloarthritis A retrospective study
dc.creator.none.fl_str_mv Alegre-Sancho, JJ
Juanola, X
Rodriguez-Heredia, JM
Manero, J
Villa-Blanco, I
Laiz, A
Arteaga, MJ
Cea-Calvo, L
Gonzalez, CM
author Alegre-Sancho, JJ
author_facet Alegre-Sancho, JJ
Juanola, X
Rodriguez-Heredia, JM
Manero, J
Villa-Blanco, I
Laiz, A
Arteaga, MJ
Cea-Calvo, L
Gonzalez, CM
author_role author
author2 Juanola, X
Rodriguez-Heredia, JM
Manero, J
Villa-Blanco, I
Laiz, A
Arteaga, MJ
Cea-Calvo, L
Gonzalez, CM
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv ankylosing spondylitis
anti- tumor necrosis factor
golimumab
psoriatic arthritis
spondyloarthritis
tumor necrosis factor inhibitor
topic ankylosing spondylitis
anti- tumor necrosis factor
golimumab
psoriatic arthritis
spondyloarthritis
tumor necrosis factor inhibitor
description This observational, longitudinal retrospective, noncomparative study was designed to assess the persistence and effectiveness of golimumab as a second anti-tumor necrosis factor (TNF) drug in patients with spondyloarthritis requiring discontinuation from a first anti-TNF drug. Data were collected retrospectively for all patients with axial spondyloarthritis or psoriatic arthritis from 20 rheumatology clinics in Spain who started golimumab as a second anti-TNF drug between January 2013 and December 2015. Golimumab persistence was assessed with Kaplan-Meier survival analysis, and associated factors were assessed with Cox regression analysis. 210 patients started golimumab as a second anti-TNF drug: 131 with axial spondyloarthritis and 79 with psoriatic arthritis. In axial spondyloarthritis patients, the mean (standard deviation) Bath Ankylosing Spondylitis Disease Activity Index score at baseline was 5.5 (2.1), decreasing to 3.9 (2.0) at month 3 and 3.5 (2.0) at year 1, and remaining stable thereafter. In psoriatic arthritis patients, mean (standard deviation) baseline Disease Activity Score was 4.0 (1.3), reducing to 2.5 (1.2) at month 3 and to 2.2 (1.3) at year 1. Corresponding improvements were recorded from baseline in C-reactive protein levels and erythrocyte sedimentation rates. The probability of persistence of treatment with golimumab was 80% at year 1, 70% at year 2 and 65% at years 3 and year 4, and was similar in those who had stopped the first anti-TNF due to loss of efficacy or other reasons. Cox regression analysis showed that the probability of survival with golimumab was higher in patients with higher erythrocyte sedimentation rate, in patients with axial spondyloarthritis than with psoriatic arthritis, and in those who had discontinued adalimumab as first anti-TNF. Seventy-two patients (34.3%) discontinued golimumab during follow-up, 50 of them due to lack of efficacy. In patients with spondyloarthritis requiring discontinuation from a first anti-TNF drug, treatment with golimumab was effective and showed a high probability of persistence up to 4 years of treatment.
publishDate 2021
dc.date.none.fl_str_mv 2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4799
https://ddd.uab.cat/record/272006
url https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4799
https://ddd.uab.cat/record/272006
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv LIPPINCOTT WILLIAMS & WILKINS
publisher.none.fl_str_mv LIPPINCOTT WILLIAMS & WILKINS
dc.source.none.fl_str_mv MEDICINE
ISSN: 00257974
ISSNe: 15365964
reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
instname_str Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
reponame_str r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
collection r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869419830568812544
score 15,811543

Similares en LA Referencia